Recombinant erythropoietin and blood transfusion in selected preterm infants

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 88, Issue 1, 2003, Pages

  Meyer, M P ^a,b   Sharma, E ^b   Carsons, M ^b  

^a MIDDLEMORE HOSPITAL   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ARTICLE; BIRTH WEIGHT; BLOOD TRANSFUSION; CONTROLLED STUDY; GESTATIONAL AGE; HIGH RISK POPULATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEWBORN INTENSIVE CARE; PATIENT SELECTION; PREMATURITY; PRIORITY JOURNAL; RETICULOCYTE COUNT; SAMPLE SIZE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0037230229     PISSN: 00039888     EISSN: 13592998     Source Type: Journal    
DOI: 10.1136/fn.88.1.f41     Document Type: Article

References (14)

1. Maier R, Obladen M, Scigalla P, et al. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very low birth weight infants. N Engl J Med 1994;330:1173-8.
2. Meyer MP, Meyer JH, Commerford A, et al. Recombinont human erythropoietin in the treatment of the anemia of prematurity: results of a double-blind, placebo controlled study. Pediatrics 1994;93:918-23.
3. Shannon KM, Keith JF, Mentzer WC, et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics 1995;95:1-8.
4. Ohls R, Osborne KA, Christensen RD. Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized placebo-controlled trial. J Pediatr 1995;126:421-6.
5. Williamson P, Griffiths G, Norfolk D, et al. Blood transfusions and human recombinant erythropoietin in premature newborn infants. Arch Dis Child Fetal Neonatal Ed 1996;75:F65-8.
6. Ohls RK, Harcum J, Schibler KR, et al. The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 g or less: a randomized, double-blind, placebo-controlled study. J Pediatr 1997;131:661-5.
7. Maier RF, Obladen M, Kattner E, et al. High- versus low-dose erythropoietin in extremely low birth weight infants. The European multicenter rhEPO study group. J Pediatr 1998;132:866-70.
8. Meyer MP, Howorth C, McNeill L. Is the use of erythropoietin in anaemia of prematurity cost effective? S Afr Med J 1996;86:251-3.
9. Al-Kharfy T, Smyth JA, Wadsworth L, et al. Erythropoietin therapy in neonates at risk of hoving bronchopulmonary dysplasia and requiring multiple transfusions. J Pediatr 1996;129:89-96.
10. Brown MS, Shapiro H. Effects of protein intake on erythropoiesis during erythropoietin treatment of anemia of prematurity. J Pediatr 1996;128:512-17.
11. Bechensteen AG, Haga P, Halvorsen S, et al Erythropoietin, protein, and iron supplementation and the prevention of the anaemia of prematurity. Arch Dis Child 1993;69:19-23.
12. Ohls RK, Ehrenkranz RA, Wright LL, et al. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics 2001;108:934-42.
13. Donalto H, Vain N, Rendo P, et al. Effect of early versus late administration of human recombinant erythropoietin on transfusion requirements in premature infants: results of a randomized, placebo-controlled, multicenter trial. Pediatrics 2000;105:1066-72.
14. Brown MS, Keith JF III. Comparison between two and five doses a week of recombinant human erythropoietin for anemia of prematurity: a randomized trial. Pediatrics 1999;104:210-15.